¼¼°èÀÇ Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° ¹× ¼­ºñ½ºº°, ¿öÅ©Ç÷οì À¯Çüº°, À¯Çüº°, ºÐ¸®¿øº°, ÀûÀÀÁõº°, ¿ëµµº°, Áö¿ªº° ºÎ¹® ¿¹Ãø(2024-2030³â)
Mesenchymal Stem Cells Market Size, Share & Trends Analysis Report By Product & Services, By Workflow Type, By Type, By Source Of Isolation, By Indication, By Application, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1493228
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Áß°£¿± Áٱ⼼Æ÷ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è °£¿± Áٱ⼼Æ÷(MSC) ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 12.92%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÇ¾úÀ¸¸ç, 2030³â¿¡´Â 72¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áß°£¿± Áٱ⼼Æ÷(MSC)¿¡ ±Ù°ÅÇÑ Á¶»ç¿Í Àç»ýÀÇ·á ºÐ¾ß¿¡¼­ÀÇ ÀǹÌÀÇ ±Þ°ÝÇÑ Áõ°¡°¡ ¾÷°è È®´ë¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ¼¼Æ÷Ä¡·á°¡ Áö¼ÓÀûÀ¸·Î ÁøÈ­Çϰí ÀÖ´Â °Íµµ Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ë±Ô¸ð »ç¾÷ ȸ»ç´Â ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨À» ³ôÀ̱â À§ÇØ Àμö¶ó´Â »ç¾÷ Àü·«À¸·Î ¼Ò±Ô¸ð ±â¾÷°ú ½ÅÈï ±â¾÷À» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

Áß°£¿± Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Á¦Ç°ÀÇ °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀº Áß°£¿± Áٱ⼼Æ÷ÀÇ »õ·Î¿î ÀÀ¿ë°ú ÇÔ²² ¾÷°èÀÇ ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ FDA´Â 2022³â¿¡ »ý¸íÀ» À§ÇùÇÏ´Â ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ ¾à 19°³ÀÇ Áٱ⼼Æ÷ Ä¡·á¸¦ ½ÂÀÎÇß½À´Ï´Ù. ±× Áß¿¡´Â BMSÀÇ BREYANZI, NovartisÀÇ ALLOCORD, KYMIRAH µîÀÌ Æ÷ÇԵ˴ϴÙ. °Ô´Ù°¡ ¸¹Àº ±â¾÷µéÀÌ ¿°Áõ¼º ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ Ä¡·á ½Ã½ºÅÛÀ¸·Î¼­ MSCÀÇ ÀáÀç·ÂÀ» ¸ð»öÇϰí ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2022³â 1¿ù, Century Therapeutics¿Í Bristol Myers Squibb´Â IPSC À¯·¡ µ¿Á¾ ¼¼Æ÷ ¿ä¹ýÀ» È®´ëÇϱâ À§ÇÑ Á¦ÈÞ¸¦ ¸Î¾ú½À´Ï´Ù. ¶ÇÇÑ, Takeda/TiGenixÀÇ 3»ó ÀÓ»ó½ÃÇè¿¡¼­´Â Å©·Ðº´¿¡ À־ º¹ÀâÇÑ Ç×¹®ÁÖÀ§ ´©°øÀ» ´ë»óÀ¸·Î Áß°£¿± Áٱ⼼Æ÷°¡ È¥ÀԵǾú½À´Ï´Ù. À̰ÍÀº 2020³â 9¿ù ÇöÀç °¡Àå ¼º°øÀûÀÎ Èıâ ÀÓ»ó½ÃÇèÀÔ´Ï´Ù. ¶ÇÇÑ 2022³â 8¿ù, AGC Biologics´Â Àΰ£ °£¿± Áٱ⠼¼Æ÷ °ø±Þ¾÷üÀÎ RoosterBio Inc.¿Í Çù·ÂÇÏ¿© »ý¸íÀ» À§ÇùÇÏ´Â Áúº´¿¡ ´ëÇÑ ÀÓ»óÀûÀ¸·Î ÀÔÁõµÈ °í±Þ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº ÁÖ¿ä ±â¾÷ÀÌ Á¦°øÇÏ´Â Áٱ⼼Æ÷ Á¦Ç°ÀÇ ÀÌ¿ëÀ» ÃËÁøÇÏ°í ½ÃÀå °æÀïÀÌ °ÝÈ­µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ÁøÃâ±â¾÷Àº ½ÃÀå Æ÷Áö¼ÇÀ» À¯ÁöÇϱâ À§ÇØ ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß ¹× ±âŸ ÁÖ¿ä ±â¾÷°úÀÇ Á¦ÈÞ ¹× ÆÄÆ®³Ê½Ê Çü¼ºÀ» ÅëÇØ Á¦°ø Á¦Ç°ÀÇ È®´ë¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. COVID-19ÀÇ ÃÖ±Ù À¯ÇàÀ¸·Î ¿©·¯ ¿¬±¸±â°ü°ú Çмú¿¬±¸±â°üÀÌ Áß°£¿± Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ýÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

Áß°£¿± Áٱ⠼¼Æ÷ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå : Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå : ÁÖ¿ä ¿ä¾à

Á¦3Àå Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå : º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Á¦Ç° ¹× ¼­ºñ½ºÀÇ ºñÁî´Ï½º ºÐ¼®

Á¦5Àå ¿öÅ©ÇÃ·Î¿ì ºñÁî´Ï½º ºÐ¼®

Á¦6Àå À¯Çü ºñÁî´Ï½º ºÐ¼®

Á¦7Àå ºÐ¸®ÀÇ ¿øÀÎ ºñÁî´Ï½º ºÐ¼®

Á¦8Àå ÀûÀÀÁõ ºñÁî´Ï½º ºÐ¼®

Á¦9Àå ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦10Àå Á¦Ç°°ú ¼­ºñ½º, ¿öÅ©Ç÷οìÀÇ À¯Çü, À¯Çü, ºÐ¸®¿ø, ¡ÈÄ, ¿ëµµº° Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦11Àå °æÀï ±¸µµ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Mesenchymal Stem Cells Market Growth & Trends:

The global mesenchymal stem cells (MSC) market size is expected to reach USD 7.27 billion by 2030, expanding at a CAGR of 12.92% from 2024 to 2030, according to a new report by Grand View Research, Inc. An exponential increase in Mesenchymal Stem Cell (MSC) based research and its implications in the field of regenerative medicine is anticipated to fuel the industry expansion. Moreover, the constantly evolving landscape of cell therapies is also anticipated to propel investments in the mesenchymal stem cells market space; large-scale operational firms are targeting small or emerging players with an operating strategy of acquisition to bolster their market presence.

The strong pipeline of mesenchymal stem cell-based products coupled with emerging applications of mesenchymal stem cells is anticipated to accelerate the industry growth. For instance, in 2022, the U.S. FDA has approved around 19 stem cell therapies for range of life-threatening disorders. Some of these therapies include, BREYANZI of BMS, ALLOCORD, KYMIRAH of Novartis etc. Moreover, a substantial number of companies are exploring the potential of MSCs as therapeutic regime for the management of inflammatory conditions, in turn, boosting market growth.

For instance, on January 2022, the Century Therapeutics and Bristol Myers Squibb entered a collaboration to expand IPSC-derives allogenic cell therapies. In addition, Takeda/TiGenix phase 3 clinical trial incorporated mesenchymal stem cells for complex perianal fistulas in Crohn's Disease. This was the most successful late-stage clinical trial as of September 2020. In addition, in August 2022 AGC Biologics partnered with human mesenchymal stem cell supplier, RoosterBio Inc. to deliver clinically proven advanced therapies for life-threatening conditions. These factors are projected to bolster the usage of stem cell products offered by key entities, thereby intensifying the market competition.

Market players are focused on the expansion of their offerings through extensive R&D and the formation of alliances and partnerships with other major players to sustain their market position. Owing to the recent pandemic of COVID-19, several research and academic research institutes are making focused efforts to develop a treatment regime by using mesenchymal stem cells.

Mesenchymal Stem Cells Market Report Highlights:

Table of Contents

Chapter 1. Mesenchymal Stem Cells Market: Methodology and Scope

Chapter 2. Mesenchymal Stem Cells Market: Executive Summary

Chapter 3. Mesenchymal Stem Cells Market: Variables, Trends, & Scope

Chapter 4. Product & Services Business Analysis

Chapter 5. Workflow Business Analysis

Chapter 6. Type Business Analysis

Chapter 7. Source of Isolation Business Analysis

Chapter 8. Indication Business Analysis

Chapter 9. Application Business Analysis

Chapter 10. Regional Business Analysis by Product & Services, Workflow Type, Type, Source of Isolation, Indication, and Application

Chapter 11. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â